Zynerba Pharmaceuticals, Inc. (ZYNE)

$0.5829

-0.04 (-6.91%)
Rating:
Recommendation:
Neutral
Symbol ZYNE
Price $0.5829
Beta 1.724
Volume Avg. 0.33M
Market Cap 27.433M
Shares () -
52 Week Range 0.49-2.94
1y Target Est -
DCF Unlevered ZYNE DCF ->
DCF Levered ZYNE LDCF ->
ROE -58.25% Strong Sell
ROA -57.46% Strong Sell
Operating Margin -
Debt / Equity 18.22% Neutral
P/E -
P/B 0.48 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ZYNE news


Mr. Armando Anido
Healthcare
Drug Manufacturers—Specialty & Generic
NASDAQ Global Market

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.